Today’s Top Movers (4/27): Axsome Therapeutics, Sasol, and Kohl’s

Today’s top three movers are Axsome Therapeutics, Sasol Limited, and Kohl’s Corporation.

Axsome Therapeutics (AXSM) Announces Positive Results of Alzheimer’s Trial

Statistically significant improvement in Alzheimer’s disease agitation, as measured by the CMAI total score compared to placebo (p=0.010, primary endpoint).

Demonstrated rapid and substantial improvement in Alzheimer’s disease agitation starting at week 2 with statistical significance at week 3 compared to placebo (p=0.007)

Statistically significant rates of clinical response (p=0.005) on the CMAI and improvement on the modified Alzheimer’s Disease Cooperative Study-CGIC scale for agitation (p=0.036) compared to placebo.

Well-tolerated and not associated with cognitive impairment or sedation.

No treatments are currently approved for Alzheimer’s disease agitation.

Full story here.

Sasol (SSL) Limited Up More Than 15% Intraday

Sasol Ltd. is a holding company. The firm engages in the provision of liquid fuels, chemicals, and low-carbon electricity.

The company provided an Operations Safety Update and an update on the effect of COVID-19 on global operations. You can read that here.

Moody’s affirms Kohl’s (KSS) Baa2 rating; assigns a Baa2 to its proposed senior unsecured notes offering

Moody’s Investors Service, (“Moody’s”) today affirmed Kohl’s Corporation (“Kohl’s”) Baa2 senior unsecured rating and assigned a Baa2 rating to its proposed $500 million senior unsecured notes offering. The outlook remains negative. The net proceeds will be used to repay a portion of its senior secured asset based revolving credit facility with the remainder for general corporate purposes.

“Kohl’s continues to take decisive actions to enhance its liquidity profile as its weathers the disruption related to COVID-19 and the potential suppression of consumer demand for an extended period, ” said Vice President, Christina Boni. “The recent replacement of its $1 billion unsecured credit facility with a $1.5 billion asset based revolver in conjunction with the $500 million of senior unsecured notes offering increases its liquidity to weather the disruption” Boni added.

The affirmation reflects Moody’s expectation that as Kohl’s business normalizes following the disruption caused by COVID-19, the company’s financial strategy will remain focused on permanent debt reduction as it has in recent years.

Read Moody’s full report by clicking here.


51 Winners in One Day with this Proven Strategy

After a 15 year deep-dive study of investing strategies, one “brain-dead simple” strategy stands alone.

Not only does this strategy automatically boost investors’ returns by nearly 3X…

It also reduces their downside risk — which is more important now than it has been in years — AND eliminates the guessing that leads to bad investment decisions.

Using the single most powerful stock indicator (which less than 1% have heard of)…

My company recently used this strategy to recommend 51 profitable trades in a single day.

The secret: this is what Wall Street’s richest investors really use to build fortunes in today’s market.
 

Click here to see which stocks this strategy recommends today.

$2 EV Stock No One's Talking About

This company is a sneaky EV play that no one’s talking about. They’re producing an odd variation on the traditional EV that has consumers raving.

Enter your email address to receive this company’s name and ticker symbol for free.



By submitting your email address, you give Stock Market Junkie permission to deliver the report or research you’re requesting to your email inbox. As a bonus, you will also get a free subscription to one of our carefully selected marketing partners. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works

$30 Stock Freaking Out Billionaires

This stock is an industry leader in a robotics technology that is freaking out billionaires (trading for just $30).

Enter your email address to receive this company’s name and ticker symbol for free.



By submitting your email address, you give Stock Market Junkie permission to deliver the report or research you’re requesting to your email inbox. As a bonus, you will also get a free subscription to one of our carefully selected marketing partners. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works

The Best TaaS Stock Right Now

This company is set to corner the market in a self-driving technology that  could fundamentally change our entire society – much like the internet did.

Enter your email address to receive this company’s name and ticker symbol for free.



By submitting your email address, you give Stock Market Junkie permission to deliver the report or research you’re requesting to your email inbox. As a bonus, you will also get a free subscription to one of our carefully selected marketing partners. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works

Up to 20,000 IPOs All in One Day

A radical $2.1 quadrillion shift is coming to the financial markets.

Some are calling it G.T.E. and Mark Cuban, Elon Musk, Richard Branson, and even banks like J.P. Morgan are invested in the tech behind it.

Just $25 could get you in alongside these billionaires. 

Enter your email address to receive the video that reveals it all.



By submitting your email address, you give Stock Market Junkie permission to deliver the report or research you’re requesting to your email inbox. As a bonus, you will also get a free subscription to one of our carefully selected marketing partners. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works

53-cent Biotech Stock with $2 Price Target

Steve Cohen, the billionaire stock picker known for running one of the most successful hedge funds ever, has poured millions into the first stock, and it’s trading for only 53 cents.

Enter your email address to receive this company’s name and ticker symbol for free.



By submitting your email address, you give Stock Market Junkie permission to deliver the report or research you’re requesting to your email inbox. As a bonus, you will also get a free subscription to one of our carefully selected marketing partners. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works